ETFs in Spotlight as FDA Vision Loss Warning Meets Lilly's Sleep Apnea Win
Two developments this week are forcing investors to reconsider how they gain exposure to the weight-loss drug boom. On one side, Eli Lilly’s (LLY) oral GLP-1 pill Foundayo delivered striking Phase 3 results, significantly reducing obstructive sleep apnea severity in patients with obesity.On the oth…
Two developments this week are forcing investors to reconsider how they gain exposure to the weight-loss drug boom. On one side, Eli Lilly’s (LLY) oral GLP-1 pill Foundayo delivered striking Phase 3 results, significantly reducing obstructive sleep apnea severity in patients with obesity.On the oth…
What's Your Reaction?
